祥生医疗
(688358)
| 流通市值：31.81亿 | | | 总市值：31.85亿 |
| 流通股本：1.12亿 | | | 总股本：1.12亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 241,448,492.64 | 127,282,003.17 | 435,809,891.23 | 343,166,004.6 |
| 营业收入 | 241,448,492.64 | 127,282,003.17 | 435,809,891.23 | 343,166,004.6 |
| 二、营业总成本 | 180,385,311.28 | 87,572,600.8 | 321,427,284.76 | 244,789,561.66 |
| 营业成本 | 96,448,213.85 | 49,631,020.36 | 178,254,505.67 | 137,881,936.57 |
| 税金及附加 | 931,830.1 | 385,772 | 2,498,274.04 | 1,829,009.12 |
| 销售费用 | 24,931,412 | 10,878,618.98 | 54,514,086.28 | 41,068,524.06 |
| 管理费用 | 19,245,604.81 | 8,385,884.63 | 36,614,184.57 | 23,966,289.97 |
| 研发费用 | 39,889,516.31 | 20,287,126.32 | 74,489,590.43 | 56,570,044.39 |
| 财务费用 | -1,061,265.79 | -1,995,821.49 | -24,943,356.23 | -16,526,242.45 |
| 其中:利息费用 | 138,401.26 | 59,019.12 | 309,910.7 | 153,460.33 |
| 其中:利息收入 | 10,726,989.86 | 6,082,685.72 | 31,667,431.46 | 23,807,207.71 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 226,776.94 | - | - | -131,310.41 |
| 加:投资收益 | 345,657.79 | 233,484.1 | 3,429,755.01 | 3,012,343.54 |
| 资产处置收益 | 421,892.84 | -5,690.34 | 4,525,956.56 | 3,662,584.52 |
| 资产减值损失(新) | -1,991,278.82 | -1,874,706.45 | -4,314,477.93 | -2,188,610.52 |
| 信用减值损失(新) | -2,416,954.09 | -2,383,243.7 | -1,817,548.58 | -3,515,435.6 |
| 其他收益 | 14,002,003.95 | 12,688,966.46 | 10,737,007.7 | 6,824,883.43 |
| 四、营业利润 | 71,651,279.97 | 48,368,212.44 | 126,943,299.23 | 106,040,897.9 |
| 加:营业外收入 | 6,106,767.89 | 1,808,230.41 | 2,027,708.45 | 148,740.81 |
| 减:营业外支出 | 839,040.99 | 51,652.08 | 323,483.97 | 936,660.46 |
| 五、利润总额 | 76,919,006.87 | 50,124,790.77 | 128,647,523.71 | 105,252,978.25 |
| 减:所得税费用 | 7,961,394.02 | 4,098,517.12 | 12,147,771.65 | 11,332,515.79 |
| 六、净利润 | 68,957,612.85 | 46,026,273.65 | 116,499,752.06 | 93,920,462.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 68,957,612.85 | 46,026,273.65 | 116,499,752.06 | 93,920,462.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 68,957,612.85 | 46,026,273.65 | 116,499,752.06 | 93,920,462.46 |
| 扣除非经常损益后的净利润 | 53,201,987.74 | 33,913,583.93 | 103,042,247.43 | 86,966,625.94 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.62 | 0.41 | 1.04 | 0.84 |
| (二)稀释每股收益 | 0.62 | 0.41 | 1.04 | 0.84 |
| 八、其他综合收益 | -20,178,612.36 | -10,339,696.43 | -13,411,702.03 | -4,277,383.19 |
| 归属于母公司股东的其他综合收益 | -20,178,612.36 | -10,339,696.43 | -13,411,702.03 | -4,277,383.19 |
| 九、综合收益总额 | 48,779,000.49 | 35,686,577.22 | 103,088,050.03 | 89,643,079.27 |
| 归属于母公司股东的综合收益总额 | 48,779,000.49 | 35,686,577.22 | 103,088,050.03 | 89,643,079.27 |
| 公告日期 | 2026-08-28 | 2026-04-28 | 2026-04-20 | 2025-10-20 |
| 审计意见(境内) | | | 标准无保留意见 | |